Medical management of colorectal liver metastasis

Wen Wee Ma, Wells A. Messersmith

Research output: Chapter in Book/Report/Conference proceedingChapter

2 Citations (Scopus)

Abstract

Colorectal cancer is the third most common cancer in the United States, and about 145, 000 new cases are expected each year (1). Approximately 15% to 30% of all colorectal cancer patients have synchronous liver metastases at initial diagnosis, and up to 60% will develop hepatic metastases at some point during their disease course (2–4). Therefore, liver metastases from colorectal cancer are a common oncologic problem. Because management of patients with colorectal liver metastases frequently involves medical oncologists, surgical oncologists, interventional radiologists and other specialists, a multidisciplinary setting is optimal. Palliative chemotherapy remains the mainstay of treatment for patients with widely metastatic colorectal cancer, and survival has increased significantly with the introduction of novel agents. However, 5-year survival of such patients remains anecdotal. Advances in surgical and interventional techniques, however, have made cure a possibility for some colorectal cancer patients with liver-only metastases. Patients with initially resectable colorectal liver metastases have achieved impressive 5-year survival rates of 30% to 70% following metastatectomy (4–6). Unfortunately, only 20% to 30% of patients with colorectal liver metastases are candidates for resection at initial presentation (7, 8). Preoperative or neoadjuvant chemotherapy may improve the rate of successful metastatectomy, limit the extent of hepatectomy and improve postoperative recovery in this group of patients. In patients with unresectable liver metastases, neoadjuvant chemotherapy can potentially render previously unresectable liver metastases amenable to surgery. The 5-year survival rate of those who subsequently undergo hepatic metastatectomy has been reported to be 20% to 40% (9).

Original languageEnglish (US)
Title of host publicationInterventional Oncology
Subtitle of host publicationPrinciples and Practice
PublisherCambridge University Press
Pages222-242
Number of pages21
ISBN (Electronic)9780511722226
ISBN (Print)9780521864138
DOIs
StatePublished - Jan 1 2008
Externally publishedYes

Fingerprint

Neoplasm Metastasis
Liver
Colorectal Neoplasms
Drug Therapy
Survival Rate
Survival
Hepatectomy
Neoplasms

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Ma, W. W., & Messersmith, W. A. (2008). Medical management of colorectal liver metastasis. In Interventional Oncology: Principles and Practice (pp. 222-242). Cambridge University Press. https://doi.org/10.1017/CBO9780511722226.020

Medical management of colorectal liver metastasis. / Ma, Wen Wee; Messersmith, Wells A.

Interventional Oncology: Principles and Practice. Cambridge University Press, 2008. p. 222-242.

Research output: Chapter in Book/Report/Conference proceedingChapter

Ma, WW & Messersmith, WA 2008, Medical management of colorectal liver metastasis. in Interventional Oncology: Principles and Practice. Cambridge University Press, pp. 222-242. https://doi.org/10.1017/CBO9780511722226.020
Ma WW, Messersmith WA. Medical management of colorectal liver metastasis. In Interventional Oncology: Principles and Practice. Cambridge University Press. 2008. p. 222-242 https://doi.org/10.1017/CBO9780511722226.020
Ma, Wen Wee ; Messersmith, Wells A. / Medical management of colorectal liver metastasis. Interventional Oncology: Principles and Practice. Cambridge University Press, 2008. pp. 222-242
@inbook{c605b47bfd4d466b923fd79d255f5a0c,
title = "Medical management of colorectal liver metastasis",
abstract = "Colorectal cancer is the third most common cancer in the United States, and about 145, 000 new cases are expected each year (1). Approximately 15{\%} to 30{\%} of all colorectal cancer patients have synchronous liver metastases at initial diagnosis, and up to 60{\%} will develop hepatic metastases at some point during their disease course (2–4). Therefore, liver metastases from colorectal cancer are a common oncologic problem. Because management of patients with colorectal liver metastases frequently involves medical oncologists, surgical oncologists, interventional radiologists and other specialists, a multidisciplinary setting is optimal. Palliative chemotherapy remains the mainstay of treatment for patients with widely metastatic colorectal cancer, and survival has increased significantly with the introduction of novel agents. However, 5-year survival of such patients remains anecdotal. Advances in surgical and interventional techniques, however, have made cure a possibility for some colorectal cancer patients with liver-only metastases. Patients with initially resectable colorectal liver metastases have achieved impressive 5-year survival rates of 30{\%} to 70{\%} following metastatectomy (4–6). Unfortunately, only 20{\%} to 30{\%} of patients with colorectal liver metastases are candidates for resection at initial presentation (7, 8). Preoperative or neoadjuvant chemotherapy may improve the rate of successful metastatectomy, limit the extent of hepatectomy and improve postoperative recovery in this group of patients. In patients with unresectable liver metastases, neoadjuvant chemotherapy can potentially render previously unresectable liver metastases amenable to surgery. The 5-year survival rate of those who subsequently undergo hepatic metastatectomy has been reported to be 20{\%} to 40{\%} (9).",
author = "Ma, {Wen Wee} and Messersmith, {Wells A.}",
year = "2008",
month = "1",
day = "1",
doi = "10.1017/CBO9780511722226.020",
language = "English (US)",
isbn = "9780521864138",
pages = "222--242",
booktitle = "Interventional Oncology",
publisher = "Cambridge University Press",
address = "United States",

}

TY - CHAP

T1 - Medical management of colorectal liver metastasis

AU - Ma, Wen Wee

AU - Messersmith, Wells A.

PY - 2008/1/1

Y1 - 2008/1/1

N2 - Colorectal cancer is the third most common cancer in the United States, and about 145, 000 new cases are expected each year (1). Approximately 15% to 30% of all colorectal cancer patients have synchronous liver metastases at initial diagnosis, and up to 60% will develop hepatic metastases at some point during their disease course (2–4). Therefore, liver metastases from colorectal cancer are a common oncologic problem. Because management of patients with colorectal liver metastases frequently involves medical oncologists, surgical oncologists, interventional radiologists and other specialists, a multidisciplinary setting is optimal. Palliative chemotherapy remains the mainstay of treatment for patients with widely metastatic colorectal cancer, and survival has increased significantly with the introduction of novel agents. However, 5-year survival of such patients remains anecdotal. Advances in surgical and interventional techniques, however, have made cure a possibility for some colorectal cancer patients with liver-only metastases. Patients with initially resectable colorectal liver metastases have achieved impressive 5-year survival rates of 30% to 70% following metastatectomy (4–6). Unfortunately, only 20% to 30% of patients with colorectal liver metastases are candidates for resection at initial presentation (7, 8). Preoperative or neoadjuvant chemotherapy may improve the rate of successful metastatectomy, limit the extent of hepatectomy and improve postoperative recovery in this group of patients. In patients with unresectable liver metastases, neoadjuvant chemotherapy can potentially render previously unresectable liver metastases amenable to surgery. The 5-year survival rate of those who subsequently undergo hepatic metastatectomy has been reported to be 20% to 40% (9).

AB - Colorectal cancer is the third most common cancer in the United States, and about 145, 000 new cases are expected each year (1). Approximately 15% to 30% of all colorectal cancer patients have synchronous liver metastases at initial diagnosis, and up to 60% will develop hepatic metastases at some point during their disease course (2–4). Therefore, liver metastases from colorectal cancer are a common oncologic problem. Because management of patients with colorectal liver metastases frequently involves medical oncologists, surgical oncologists, interventional radiologists and other specialists, a multidisciplinary setting is optimal. Palliative chemotherapy remains the mainstay of treatment for patients with widely metastatic colorectal cancer, and survival has increased significantly with the introduction of novel agents. However, 5-year survival of such patients remains anecdotal. Advances in surgical and interventional techniques, however, have made cure a possibility for some colorectal cancer patients with liver-only metastases. Patients with initially resectable colorectal liver metastases have achieved impressive 5-year survival rates of 30% to 70% following metastatectomy (4–6). Unfortunately, only 20% to 30% of patients with colorectal liver metastases are candidates for resection at initial presentation (7, 8). Preoperative or neoadjuvant chemotherapy may improve the rate of successful metastatectomy, limit the extent of hepatectomy and improve postoperative recovery in this group of patients. In patients with unresectable liver metastases, neoadjuvant chemotherapy can potentially render previously unresectable liver metastases amenable to surgery. The 5-year survival rate of those who subsequently undergo hepatic metastatectomy has been reported to be 20% to 40% (9).

UR - http://www.scopus.com/inward/record.url?scp=78650985146&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78650985146&partnerID=8YFLogxK

U2 - 10.1017/CBO9780511722226.020

DO - 10.1017/CBO9780511722226.020

M3 - Chapter

AN - SCOPUS:78650985146

SN - 9780521864138

SP - 222

EP - 242

BT - Interventional Oncology

PB - Cambridge University Press

ER -